Literature DB >> 9239542

Mitochondrial dysfunction in neurodegeneration.

J M Cooper1, A H Schapira.   

Abstract

Numerous toxins are known to interfere with mitochondrial respiratory chain functions. Use has been made of these in the development of pesticides and herbicides, and accidental use in man has led to the development of animal models for human disease. The propensity for mitochondrial toxins to induce neuronal cell death may well reflect not only their metabolic pathways but also the sensitivity of neurons to inhibition of oxidative phosphorylation. Thus, the accidental exposure of humans to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and to 3-nitropropionic acid had led to primate models of Parkinson's disease and Huntington's Disease, respectively. These models were made all the more remarkable when identical biochemical deficiencies were identified in relevant areas of human suffering from the respective idiopathic diseases. The place of complex I deficiency in Parkinson's disease remains undetermined, but there is recent evidence to suggest that, in some cases at least, it may play a primary role. The complex II/III deficiency in Huntington's disease is likely to be secondary and induced by other pathogenetic factors. The potential to intervene in the cascade of reactions involving mitochondrial dysfunction and cell death offers prospects for the development of new treatment strategies either for neuroprotection in prophylaxis or rescue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9239542     DOI: 10.1023/a:1022642114734

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  104 in total

1.  Mitochondrial DNA in postmortem brain from patients with Parkinson's disease.

Authors:  P Lestienne; I Nelson; P Riederer; H Reichmann; K Jellinger
Journal:  J Neurochem       Date:  1991-05       Impact factor: 5.372

2.  Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence.

Authors:  S Ikebe; M Tanaka; K Ohno; W Sato; K Hattori; T Kondo; Y Mizuno; T Ozawa
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

Review 3.  Oxidative stress and mitochondrial dysfunction in neurodegeneration.

Authors:  A H Schapira
Journal:  Curr Opin Neurol       Date:  1996-08       Impact factor: 5.710

4.  Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid.

Authors:  D H Gould; D L Gustine
Journal:  Neuropathol Appl Neurobiol       Date:  1982 Sep-Oct       Impact factor: 8.090

5.  Choreoathetosis and striopallidonigral necrosis due to sodium azide.

Authors:  F A Mettler
Journal:  Exp Neurol       Date:  1972-02       Impact factor: 5.330

6.  1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism.

Authors:  E Storey; B T Hyman; B Jenkins; E Brouillet; J M Miller; B R Rosen; M F Beal
Journal:  J Neurochem       Date:  1992-05       Impact factor: 5.372

7.  Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.

Authors:  A H Schapira; V M Mann; J M Cooper; D Dexter; S E Daniel; P Jenner; J B Clark; C D Marsden
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

8.  Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease.

Authors:  T Ozawa; M Tanaka; H Ino; K Ohno; T Sano; Y Wada; M Yoneda; Y Tanno; T Miyatake; T Tanaka
Journal:  Biochem Biophys Res Commun       Date:  1991-04-30       Impact factor: 3.575

9.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.

Authors:  V M Mann; J M Cooper; D Krige; S E Daniel; A H Schapira; C D Marsden
Journal:  Brain       Date:  1992-04       Impact factor: 13.501

10.  L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.

Authors:  J M Cooper; S E Daniel; C D Marsden; A H Schapira
Journal:  Mov Disord       Date:  1995-05       Impact factor: 10.338

View more
  7 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations.

Authors:  Mark P Mattson; Wenzhen Duan; Ruqian Wan; Zhihong Guo
Journal:  NeuroRx       Date:  2004-01

Review 3.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 4.  Optical and pharmacological tools to investigate the role of mitochondria during oxidative stress and neurodegeneration.

Authors:  Kelley A Foster; Francesca Galeffi; Florian J Gerich; Dennis A Turner; Michael Müller
Journal:  Prog Neurobiol       Date:  2006-06       Impact factor: 11.685

5.  Reduction of lipid peroxidation in different brain regions by a combination of alpha-tocopherol and ascorbic acid.

Authors:  S Bano; M S Parihar
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Mitochondrial control of neuron death and its role in neurodegenerative disorders.

Authors:  J Jordán; V Ceña; J H M Prehn
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

7.  Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.

Authors:  Jinghua Jin; Feng-Shiun Shie; Jun Liu; Yan Wang; Jeanne Davis; Aimee M Schantz; Kathleen S Montine; Thomas J Montine; Jing Zhang
Journal:  J Neuroinflammation       Date:  2007-01-04       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.